GTCbio, Washington D.C.
November 7-9, 2007
Marking its 5th anniversary, the Vaccines: All Things Considered conference aims to make the benefits and impact of vaccines better understood and more accepted by all segments of our society. We have assembled an impressive faculty of speakers with representation from industry, academia and the public sector to address a broad range of vaccine related topics structured in the following sessions: 1. New Targets and Technologies for Vaccines
2. Development of New Vaccines for Major Markets
3. New Vaccines for Emerging Markets
4. Vaccine Policy, Regulation, and Funding
5. New Developments in the Influenza Space Plus, attend the pre-conference workshop on November 7th to gain insight on new manufacturing, methods and techniques as well as FDA guidance. Come and join us in beautiful Washington DC on November 8th and 9th to hear about the latest information on the field of vaccines and participate in stimulating discussions on where it is headed. Come earlier or stay later and enjoy the many historic and cultural delights our nation’s capital has to offer; sites such as the Smithsonian museums including the new Air and Space Annex near Dulles Airport, as well as all the other Museums on the Mall (art, Technology, Air and Space, Natural history); the Kennedy center with its multiple stages and venues, the fall colors in the near by chain of mountains and of course the Supreme Court, Capitol Library of Congress and the White House. Please bring notice of this meeting to colleagues that will benefit from attending. Please register early and submit an abstract.
|
|
|
Invited Speakers:
|
|
David C. Kaslow, M.D. [KEYNOTE]
Vice President, Infectious Diseases and Vaccines Franchise, Merck & Co.
George Robertson, Ph.D.
Senior Program Manager, BARDA, DHHS
Daniel Zimmerman, Ph.D.
Senior Vice President Research and Development, Cellular Immunology, CEL-SCI Corporation
Frank Rapoport, Esq
Partner, McKenna, Long, & Aldridge
Reiner Laus, M.D.
President and Chief Executive Officer, BN ImmunoTherapeutics
David Burt, Ph.D.
Head of Research, GlaxoSmithKline Biologicals of N. America
Brian Underdown
Managing Director, MDS Capital Corporation
John Clerici, Esq
Partner, McKenna, Long & Aldridge
Ken Rosenthal, Ph.D.
Professor, NEOUCOM
Niranjan Kanesa-thasan, MD, MTMH
Director, Clinical (Early Development Cluster), Novartis Vaccines
Rahul Singhvi
CEO, Novavax
Stan Erck
President & CEO, IOMAI
Paul Chaplin
Chief Scientific Officer, Bavarian Nordic
Brian Livingston, Ph.D.
Director, Preclinical Research, Dynavax
Angela Shen
International Policy Analyst-Vaccine Specialist, National Vaccine Program Office, DHHS
Norman Baylor, Ph.D.
Director, Office of Vaccines, CBER, FDA
Christian Loucq, M.D.
Director, MVI, The PATH Malaria Vaccine Initiative
Gail Sofer
Director, Regulatory Compliance, GE Healthcare
Chris Colwell
Director of Healthcare Regulatory Affairs, BIO
Michael Vajdy Ph.D.
Novartis Vaccines
Nicholas M. Valiante, Ph.D.
Vaccines Research Director/Project Leader, Novartis Vaccines
Alan Shaw, Ph.D.
President & Chief Executive Officer, VaxInnate
Gerald R. Kovacs, Ph.D.
Acting Associate Director, BioShield, BARDA, DHHS
Clem Lewin, Ph.D., MBA
Vice President Marketing, Policy & Strategy, Acambis
Hideki Garren, M.D., Ph.D.
Co-founder & VP of Research, Bayhill Therpeutics, Inc.
|
|